Shanghai Fosun Pharma | Sustainability Performance
Operates in pharmaceuticals, medical devices, and healthcare services.
1994
China
10,001+ employees
Pharmaceuticals
$1B - 10B in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#12435
Overallⓘ#1108
in Chinaⓘ#287
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsEnergy consumptionWaste ManagementWater ManagementAir & land impactNature and biodiversitySocial
Diversity and InclusionPay GapsHealth and SafetyExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Critical
Critical
Critical
Laggard
Aligned
Intensity
Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)
Industry Benchmark
162.1
B/M 312.2
Powered by illuminem and GIST Impact
Controversy level
- Shanghai Fosun Pharmaceutical (Group) Co Ltd, Chinese major pharma (Fosun International affiliated), has faced sustained Chinese NMPA enforcement scrutiny over the contested 2024 sustained share price volatility amid Chinese pharma market normalization, plus periodic US/EU scrutiny over the historic Fosun Pharma/BioNTech mRNA vaccine partnership Greater China rights affecting Hong Konglisted institutional shareholders.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
7-10
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.